Mineralys Therapeutics (MLYS) Projected to Post Quarterly Earnings on Wednesday

Mineralys Therapeutics (NASDAQ:MLYS) will likely be issuing its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect the company to announce earnings of ($0.51) per share for the quarter. Investors may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 6, 2026 at 4:30 PM ET.

Mineralys Therapeutics (NASDAQ:MLYS) last released its earnings results on Thursday, March 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.17. On average, analysts expect Mineralys Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Mineralys Therapeutics Price Performance

Shares of Mineralys Therapeutics stock traded down $0.33 during trading on Monday, hitting $28.93. The stock had a trading volume of 217,616 shares, compared to its average volume of 1,216,741. The firm’s fifty day simple moving average is $27.11 and its 200-day simple moving average is $33.43. The stock has a market cap of $2.39 billion, a PE ratio of -12.00 and a beta of 0.49. Mineralys Therapeutics has a 12 month low of $12.59 and a 12 month high of $47.65.

Insider Activity at Mineralys Therapeutics

In other Mineralys Therapeutics news, insider David Malcom Rodman sold 14,058 shares of the business’s stock in a transaction dated Monday, April 13th. The shares were sold at an average price of $26.54, for a total transaction of $373,099.32. Following the sale, the insider directly owned 76,140 shares in the company, valued at $2,020,755.60. This represents a 15.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daphne Karydas sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 31st. The stock was sold at an average price of $25.00, for a total transaction of $75,000.00. Following the sale, the director owned 6,200 shares in the company, valued at $155,000. The trade was a 32.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 162,291 shares of company stock worth $4,336,414. 18.94% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Mineralys Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. State Street Corp grew its position in shares of Mineralys Therapeutics by 144.4% during the fourth quarter. State Street Corp now owns 3,184,999 shares of the company’s stock worth $115,584,000 after acquiring an additional 1,881,976 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Mineralys Therapeutics by 6,097.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,325,120 shares of the company’s stock worth $48,089,000 after buying an additional 1,303,737 shares during the period. Janus Henderson Group PLC boosted its stake in shares of Mineralys Therapeutics by 6,012.8% during the fourth quarter. Janus Henderson Group PLC now owns 1,213,265 shares of the company’s stock worth $44,005,000 after buying an additional 1,193,417 shares during the period. RA Capital Management L.P. lifted its holdings in shares of Mineralys Therapeutics by 19.1% during the third quarter. RA Capital Management L.P. now owns 7,323,750 shares of the company’s stock worth $277,717,000 after purchasing an additional 1,176,470 shares during the period. Finally, Polar Capital Holdings Plc acquired a new stake in Mineralys Therapeutics in the third quarter valued at $40,149,000. 84.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on MLYS. Jefferies Financial Group restated a “hold” rating and issued a $30.00 price target on shares of Mineralys Therapeutics in a report on Friday, March 13th. Bank of America raised their price target on shares of Mineralys Therapeutics from $46.00 to $51.00 and gave the company a “buy” rating in a report on Friday, March 13th. Wall Street Zen upgraded shares of Mineralys Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. TD Cowen began coverage on shares of Mineralys Therapeutics in a report on Monday, April 27th. They issued a “buy” rating on the stock. Finally, HC Wainwright set a $56.00 price target on shares of Mineralys Therapeutics and gave the company a “buy” rating in a report on Tuesday, March 10th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $49.14.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.